PRKDC and synovial sarcoma: We selected two SS18:SSX fusion positive synovial sarcoma cell lines, SYO-1 and HS-SY-II, to evaluate if DNA-PK inhibition by peposertib could enhance the cytotoxic effects of Topo II inhibitors, such as doxorubicin or etoposide.